Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Host immune and gut barrier pathways represent a complex network of biological processes rather than a single therapeutic target. These pathways involve the physical intestinal barrier, composed of epithelial cells and tight junction proteins like claudins and occludin, as well as the mucosal immune system, which includes specialized cells such as intraepithelial lymphocytes and dendritic cells. Their primary function is to maintain homeostasis by preventing the translocation of pathogens and toxins from the gut lumen into the systemic circulation while allowing for nutrient absorption and immune tolerance to commensal bacteria. Dysregulation of these pathways is a hallmark of various gastrointestinal and systemic conditions, including inflammatory bowel disease (IBD), where increased intestinal permeability (leaky gut) and aberrant immune activation lead to chronic inflammation. While many drugs target specific components within these pathways—such as TNF-alpha inhibitors or integrin blockers—the term itself describes a broad physiological system rather than a discrete protein or receptor.
Not applicable as this is a collection of pathways rather than a single molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host immune and gut barrier pathways.